Article
Efficacy in patients with EGFR-positive non-small-cell lung cancer treated with dacomitinib who had skin adverse events: post hoc analyses from ARCHER 1050.
Future oncology (London, England) - 1 Jan 2024
Pu Xingxiang, Li Juan, Zhang Bo, Zhang Jinyao, K Mok Tony S, Nakagawa Kazuhiko, Rosell Rafael, Cheng Ying, Zhou Xiangdong, Miglorino Maria Rita, Niho Seiji, Lee Ki Hyeong, Corral Jesus, Pluzanski Adam, Li Junling, Linke Rolf, Pan Fang, Tang Yiyun, Tan Weiwei, Wu Lin
Abstract excerpt
Aim: We investigated association between skin adverse events (AEs) and efficacy with dacomitinib in patients with EGFR-positive non-small-cell lung cancer (NSCLC).Methods: Post hoc analyses from ARCHER 1050 evaluated efficacy in patients who did and did not experience grade ≥2 skin AEs with dacomitinib. Landmark analyses were performed at 3 and 6 months.Results: In patients who had skin AEs (72.2%) vs. those who...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.